Craniopharyngioma: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
* 81–95% of cases show BRAF V600E mutations. | * 81–95% of cases show BRAF V600E mutations. | ||
* Usually solid, or rarely cystic. | * Usually solid, or rarely cystic. | ||
* Occurs almost exclusively in adults with a mean age of 40–55 years. | * Occurs almost exclusively in adults with a mean age of 40–55 years. | ||
= Overview of Adult and Pediatric Craniopharyngioma = | |||
<table> | |||
<tr> | |||
<th></th> | |||
<th>Adult</th> | |||
<th>Pediatric</th> | |||
</tr> | |||
<tr> | |||
<td><strong>EPIDEMIOLOGY</strong></td> | |||
<td></td> | |||
<td></td> | |||
</tr> | |||
<tr> | |||
<td>Age in years</td> | |||
<td>65–74</td> | |||
<td>5–14</td> | |||
</tr> | |||
<tr> | |||
<td>Gender</td> | |||
<td>M = F</td> | |||
<td>M > F</td> | |||
</tr> | |||
<tr> | |||
<td>Clinical presentation</td> | |||
<td>Vision loss, hydrocephalus</td> | |||
<td>Headaches, hydrocephalus</td> | |||
</tr> | |||
<tr> | |||
<td>Endocrine dysfunction</td> | |||
<td>Less common</td> | |||
<td>Common</td> | |||
</tr> | |||
<tr> | |||
<td><strong>RADIOLOGY</strong></td> | |||
<td></td> | |||
<td></td> | |||
</tr> | |||
<tr> | |||
<td>Cysts</td> | |||
<td>Less common</td> | |||
<td>Common</td> | |||
</tr> | |||
<tr> | |||
<td>Calcification</td> | |||
<td>Less common</td> | |||
<td>Common</td> | |||
</tr> | |||
<tr> | |||
<td><strong>PATHOLOGY TYPE</strong></td> | |||
<td></td> | |||
<td></td> | |||
</tr> | |||
<tr> | |||
<td>Adamantinomatous</td> | |||
<td>Yes</td> | |||
<td>Yes</td> | |||
</tr> | |||
<tr> | |||
<td>Papillary</td> | |||
<td>Yes</td> | |||
<td>No</td> | |||
</tr> | |||
<tr> | |||
<td><strong>TREATMENT OPTIONS</strong></td> | |||
<td></td> | |||
<td></td> | |||
</tr> | |||
<tr> | |||
<td>Surgery</td> | |||
<td>Yes</td> | |||
<td>Yes</td> | |||
</tr> | |||
<tr> | |||
<td>Radiotherapy</td> | |||
<td>Yes</td> | |||
<td>Yes</td> | |||
</tr> | |||
<tr> | |||
<td>Targeted therapy</td> | |||
<td>Yes (papillary subtype)</td> | |||
<td>No</td> | |||
</tr> | |||
<tr> | |||
<td><strong>TREATMENT MORBIDITY</strong></td> | |||
<td></td> | |||
<td></td> | |||
</tr> | |||
<tr> | |||
<td>Surgery</td> | |||
<td></td> | |||
<td>Better tolerated than radiation</td> | |||
</tr> | |||
<tr> | |||
<td>Radiotherapy</td> | |||
<td>Better tolerated than surgery</td> | |||
<td></td> | |||
</tr> | |||
</table> | |||
[[Category:Neuro-Oncology]] | [[Category:Neuro-Oncology]] | ||
[[Category:Extrinsic Brain Tumors]] | |||
Revision as of 22:32, 2 March 2024
Subtypes of craniopharyngioma
Adamantinomatous craniopharyngioma
- A craniopharyngioma w/ epithelium that form stellate reticulum, wet keratin and basal palisades.
- Up to 95% of cases of this variant shows CTNNB1 mutations and aberrant nuclear expression of beta- catenin.
- Bimodal age distribution: childhood peak age 5–15 years, adult peak age 45–60 years.38
Papillary craniopharyngioma
- A craniopharyngioma w/ papillary features.
- Occurs in the supratentorial compartment or 3rd ventricle.
- 81–95% of cases show BRAF V600E mutations.
- Usually solid, or rarely cystic.
- Occurs almost exclusively in adults with a mean age of 40–55 years.
Overview of Adult and Pediatric Craniopharyngioma
| Adult | Pediatric | |
|---|---|---|
| EPIDEMIOLOGY | ||
| Age in years | 65–74 | 5–14 |
| Gender | M = F | M > F |
| Clinical presentation | Vision loss, hydrocephalus | Headaches, hydrocephalus |
| Endocrine dysfunction | Less common | Common |
| RADIOLOGY | ||
| Cysts | Less common | Common |
| Calcification | Less common | Common |
| PATHOLOGY TYPE | ||
| Adamantinomatous | Yes | Yes |
| Papillary | Yes | No |
| TREATMENT OPTIONS | ||
| Surgery | Yes | Yes |
| Radiotherapy | Yes | Yes |
| Targeted therapy | Yes (papillary subtype) | No |
| TREATMENT MORBIDITY | ||
| Surgery | Better tolerated than radiation | |
| Radiotherapy | Better tolerated than surgery |